GSA Capital Partners’s Ovid Therapeutics OVID Stock Holding History

GSA Capital Partners’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$275K	Buy	123,969 +15,635	+14%	+$28K	0.02%	1298
2025 Q4	$177K	Sell	108,334 -157,659	-59%	-$243K	0.02%	1441
2025 Q3	$346K	Sell	265,993 -476,197	-64%	-$413K	0.03%	1114
2025 Q2	$245K	Buy	742,190 +302,087	+69%	+$91K	0.02%	1392
2025 Q1	$137K	Buy	440,103 +316,520	+256%	+$195K	0.01%	1467
2024 Q4	$115K	Sell	123,583 -136,926	-53%	-$153K	0.01%	1502
2024 Q3	$307K	Buy	260,509 +141,002	+118%	+$147K	0.02%	1200
2024 Q2	$92K	Buy	+119,507	New	+$333K	0.01%	1534
2021 Q2	–	Sell	-75,888	Closed	-$305K	–	1526
2021 Q1	$305K	Sell	75,888 -115,945	-60%	-$385K	0.05%	638
2020 Q4	$443K	Buy	191,833 +134,959	+237%	+$629K	0.07%	494
2020 Q3	$326K	Buy	+56,874	New	+$381K	0.05%	677

Other funds holding OVID

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

GSA Capital Partners's OVID Position: Q1 2026 in Review

GSA Capital Partners increased its Ovid Therapeutics (OVID) stake by 14% in Q1 2026, buying an estimated $28K and bringing the position to 123,969 shares worth $275K. The position accounts for 0.02% of the portfolio, ranked #1298.

GSA Capital Partners first reported a position in OVID in Q3 2020 and has held it in 11 quarters since. The position peaked at $443K in Q4 2020. 103 funds tracked by Wall St. Rank hold OVID as of Q1 2026.

GSA Capital Partners held 123,969 shares of Ovid Therapeutics worth $275K as of Q1 2026.
GSA Capital Partners bought 15,635 Ovid Therapeutics shares in Q1 2026, an estimated $28K.
Ovid Therapeutics made up 0.02% of GSA Capital Partners's portfolio in Q1 2026, its #1298 holding.
GSA Capital Partners first reported a position in Ovid Therapeutics in Q3 2020 and has held it in 11 quarters since.
GSA Capital Partners's Ovid Therapeutics position peaked at $443K in Q4 2020.
103 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.